TNSN05006A1 - Comprime de lasofoxifene et son enrobage - Google Patents

Comprime de lasofoxifene et son enrobage

Info

Publication number
TNSN05006A1
TNSN05006A1 TNP2005000006A TNSN05006A TNSN05006A1 TN SN05006 A1 TNSN05006 A1 TN SN05006A1 TN P2005000006 A TNP2005000006 A TN P2005000006A TN SN05006 A TNSN05006 A TN SN05006A TN SN05006 A1 TNSN05006 A1 TN SN05006A1
Authority
TN
Tunisia
Prior art keywords
lasofoxifene
coating
active ingredient
tablet
compositions
Prior art date
Application number
TNP2005000006A
Other languages
English (en)
Inventor
Daniel Scott Gierer
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN05006A1 publication Critical patent/TNSN05006A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Des compositions pharmaceutiques ayant une distribution et activité uniforme de médicament, utilisant du lasofoxifène comme ingrédient actif et contenant un dioxyde de silicium pour réduire la perte d'ingrédient actif au cours du procédé de production, ainsi que des procédés pour la production de ces compositions sont décrits. La triacétine d'enrobage, servant de plastifiant, se révèle conférer une bonne stabilité au lasofoxifène.
TNP2005000006A 2002-07-10 2005-01-10 Comprime de lasofoxifene et son enrobage TNSN05006A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39509002P 2002-07-10 2002-07-10
PCT/IB2003/003074 WO2004006895A1 (fr) 2002-07-10 2003-06-30 Comprime de lasofoxifene et enrobage de celui-ci

Publications (1)

Publication Number Publication Date
TNSN05006A1 true TNSN05006A1 (fr) 2007-05-14

Family

ID=30115812

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2005000006A TNSN05006A1 (fr) 2002-07-10 2005-01-10 Comprime de lasofoxifene et son enrobage

Country Status (36)

Country Link
US (2) US20040057992A1 (fr)
EP (1) EP1534248B1 (fr)
JP (2) JP4446446B2 (fr)
KR (1) KR100782693B1 (fr)
CN (1) CN100344278C (fr)
AP (1) AP2005003201A0 (fr)
AR (1) AR040434A1 (fr)
AT (1) ATE550017T1 (fr)
AU (1) AU2003247017B2 (fr)
BR (1) BR0312563A (fr)
CA (1) CA2489407C (fr)
CY (1) CY1112892T1 (fr)
DK (1) DK1534248T3 (fr)
EA (1) EA007268B1 (fr)
EC (1) ECSP055528A (fr)
ES (1) ES2395123T3 (fr)
HK (1) HK1077747A1 (fr)
HN (1) HN2003000206A (fr)
HR (1) HRP20041196A2 (fr)
IL (2) IL165746A0 (fr)
IS (1) IS7594A (fr)
MA (1) MA27318A1 (fr)
MX (1) MXPA05000394A (fr)
NO (1) NO20050018L (fr)
NZ (1) NZ537278A (fr)
OA (1) OA12883A (fr)
PA (1) PA8576201A1 (fr)
PE (1) PE20040104A1 (fr)
PL (1) PL374913A1 (fr)
PT (1) PT1534248E (fr)
SI (1) SI1534248T1 (fr)
TN (1) TNSN05006A1 (fr)
TW (1) TW200406222A (fr)
UY (1) UY27886A1 (fr)
WO (1) WO2004006895A1 (fr)
ZA (1) ZA200410196B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
EP1871359A1 (fr) * 2005-04-07 2008-01-02 Miso Sabovic Retardement du processus de vieillissement et des troubles provoques par le vieillissement
WO2006118137A1 (fr) * 2005-04-26 2006-11-09 Dainippon Sumitomo Pharma Co., Ltd. Préparation granulaire contenant un dérivé de biguanide
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
EP3173084B1 (fr) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Dérivés de quinazoline pour le traitement de cancers
LT2487166T (lt) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
CA2835910C (fr) * 2007-04-25 2016-06-28 Warner Chilcott Company, Llc Uniformite amelioree de contenu de vitamine d dans des formes dosifiees pharmaceutiques
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
CN101820863A (zh) * 2007-10-10 2010-09-01 马林克罗特贝克公司 直接可压制的高功能性颗粒状微晶纤维素基赋形剂、其制备方法和用途
WO2009135067A1 (fr) * 2008-05-01 2009-11-05 Wyeth Formulations de vernis pharmaceutique
SG190618A1 (en) * 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
US9545381B2 (en) * 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
RU2661402C2 (ru) * 2011-10-17 2018-07-16 Лексикон Фармасьютикалз, Инк. Твердые дозированные формы (s)-этил 2-амино-3-(4-(2-амино-6((r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата
DK2851075T3 (da) 2012-05-14 2022-01-31 Shionogi & Co Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
PL3043778T3 (pl) * 2013-09-13 2018-04-30 Bayer Pharma Aktiengesellschaft Kompozycje farmaceutyczne zawierające refametinib
RU2539375C1 (ru) * 2013-11-07 2015-01-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция в форме таблетки и способ ее получения
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
US20190183850A1 (en) * 2016-07-25 2019-06-20 Canopy Growth Corporation New cannabis tablet formulations and compositions and methods of making the same
JP6892151B2 (ja) 2016-10-11 2021-06-23 デューク ユニバーシティ Ｅｒ＋乳がんのラソフォキシフェン処置
EP3773524A4 (fr) 2018-04-10 2021-12-22 Duke University Traitement du cancer du sein avec du lasofoxifène
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
CN114288258A (zh) * 2022-02-18 2022-04-08 山东新时代药业有限公司 一种单硝酸异山梨酯片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182A (en) * 1845-09-09 Island
US4880636A (en) * 1988-05-13 1989-11-14 Franz Robert M Film coated tablet of ranitidine HCl
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US6372457B1 (en) 1997-01-14 2002-04-16 Arkion Life Sciences Llc Process and materials for production of glucosamine
KR200161927Y1 (ko) * 1997-08-26 1999-12-01 윤종용 냉장고
YU26700A (sh) * 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
EP1145719A3 (fr) * 2000-03-10 2001-11-14 Pfizer Products Inc. Utilisation d'un sel ferreux pour l'inhibition de la dégradation oxydative de compositions pharmaceutiques
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
OA12596A (en) * 2001-05-01 2006-06-08 Pfizer Prod Inc Method for manufacturing a low dose pharmaceuticalcomposition.
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco

Also Published As

Publication number Publication date
OA12883A (en) 2006-09-15
EA200401583A1 (ru) 2005-06-30
PA8576201A1 (es) 2004-05-26
HK1077747A1 (en) 2006-02-24
MXPA05000394A (es) 2005-03-23
PL374913A1 (en) 2005-11-14
ECSP055528A (es) 2005-03-10
DK1534248T3 (da) 2012-06-25
MA27318A1 (fr) 2005-05-02
SI1534248T1 (sl) 2012-07-31
NZ537278A (en) 2007-07-27
EP1534248B1 (fr) 2012-03-21
CY1112892T1 (el) 2016-04-13
IL165746A (en) 2008-12-29
US20040057992A1 (en) 2004-03-25
TW200406222A (en) 2004-05-01
JP2005535671A (ja) 2005-11-24
CA2489407A1 (fr) 2004-01-22
AU2003247017B2 (en) 2008-03-06
IL165746A0 (en) 2006-01-15
NO20050018L (no) 2005-01-12
ES2395123T3 (es) 2013-02-08
ZA200410196B (en) 2006-07-26
PE20040104A1 (es) 2004-02-27
WO2004006895A1 (fr) 2004-01-22
CN1668285A (zh) 2005-09-14
AR040434A1 (es) 2005-04-06
EP1534248A1 (fr) 2005-06-01
PT1534248E (pt) 2012-05-25
AP2005003201A0 (en) 2005-03-31
US20070110800A1 (en) 2007-05-17
JP4446446B2 (ja) 2010-04-07
KR100782693B1 (ko) 2007-12-07
US7553500B2 (en) 2009-06-30
ATE550017T1 (de) 2012-04-15
CN100344278C (zh) 2007-10-24
AU2003247017A1 (en) 2004-02-02
CA2489407C (fr) 2009-01-27
IS7594A (is) 2004-12-13
KR20050017102A (ko) 2005-02-21
JP2007031451A (ja) 2007-02-08
EA007268B1 (ru) 2006-08-25
UY27886A1 (es) 2004-02-27
HN2003000206A (es) 2004-07-27
HRP20041196A2 (en) 2005-04-30
BR0312563A (pt) 2005-04-19

Similar Documents

Publication Publication Date Title
TNSN05006A1 (fr) Comprime de lasofoxifene et son enrobage
BRPI0418245B8 (pt) composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes
SE0100567D0 (sv) Compounds
EE04911B1 (et) Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
TNSN03106A1 (fr) Procede pour la production d'une composition pharmaceutique a faible dose ayant une distribution et activite medicamenteuse uniforme
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
DE60103050D1 (de) Spiro[2.4]heptanaminocarbonsäure und ihre derivate
MY137348A (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
TW200510375A (en) New compounds
PE20060176A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos
SE0100568D0 (sv) Compounds
HK1070063A1 (en) Stable polymorph of flibanserin, technical processfor its preparation and the use thereof for prepa ring medicaments
PL1746980T3 (pl) Farmaceutyczna postać dawkowania zawierająca peletki i sposób jej wytwarzania
SE0100569D0 (sv) New compounds
DE60138572D1 (de) Methoden und pharmazeutische zusammensetzungen zur wundheilung
DE60211769D1 (de) Verfahren zur Herstellung von Arzneistoffgranulatkörnern, die Arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische Zubereitungen
SE0102440D0 (sv) New compound
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
AP1919A (en) Preparation compositions containing acid-unstable physiologically active compounds and process for producing the same
SE0100566D0 (sv) Compounds
PL374827A1 (en) Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
AU2003271811A8 (en) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
AU2003214535A8 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BR0311306A (pt) Derivados de amida como inibidores da atividade enzimática de renina